Exchange: NASDAQ·Updated 07:55 PM EDT

AZN News

News
all
press releases
Cancer Stocks to Consider as Oncology Innovation Accelerates
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
Zacks
Cancer Stocks to Consider as Oncology Innovation Accelerates
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
Zacks
More News
RFK Jr. Announces New Clinic For People Injured By Vaccines
RFK Jr. Announces New Clinic For People Injured By Vaccines Authored by Zachary Stieber via The Epoch Times, Health Secretary Robert F. Kennedy Jr. and other officials have opened a new clinic to treat patients with vaccine injuries and announced other new developments on Oct. 8 that...
Zero Hedge
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results
PFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline.
Zacks
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyPR NewswireBOSTON, Oct. 8, 2026BOSTON, Oct. 8, 2026...
PR Newswire
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?
LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.
Zacks
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?
IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
Zacks
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.
Zacks
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?
Merck's 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its post-2028 outlook.
Zacks
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations...
CNBC Television-YouTube
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts...
CNBC: Business

Advertisement|Remove ads.